Merck Posts Strong Q2 Earnings with $16.6 Billion in Revenue
Merck & Co., Inc.'s second-quarter sales and earnings call took place in Rahway, New Jersey. The company reported revenue of $16.6 billion for the quarter.
The chairman and CEO, Rob Davis, expressed his satisfaction with the progress made across various business areas. He highlighted strong execution, contributions from new product launches, and advancements from the pipeline.
One notable development was the FDA's approval of LIPFENDRA, an oral PCSK9 inhibitor for reducing LDL cholesterol in adults with hypercholesterolemia. This comes after Merck worked closely with the FDA to bring this treatment option to patients via the Commissioner's National Priority Voucher process.
In oncology, Merck received several approvals that underscore the ongoing impact of KEYTRUDA and its enduring strength. The company also presented encouraging data at ASCO that demonstrate the durability of KEYTRUDA.